Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients

F Frandsen, P Pless, H Mickley, M Møller

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 1990-null
OriginalsprogEngelsk
TidsskriftActa Cardiologica
Vol/bind45
Udgave nummer5
Sider (fra-til)351-7
Antal sider6
ISSN0001-5385
StatusUdgivet - 1990

Fingeraftryk

Flecainide
Ventricular Premature Complexes
Electrocardiography
History

Citer dette

@article{f6def00046fd11df937d000ea68e967b,
title = "Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients",
abstract = "The long-term clinical effect of oral flecainide treatment was evaluated in 107 pts (10-82 yrs). Indications for treatment were: atrial fibrillation 38{\%}, atrial flutter 16{\%}, ventricular tachycardia 24{\%}, ventricular ectopic beats 10{\%} and supraventricular tachycardia 12{\%}. Daily flecainide dosage was 200 (100-400) mg. Follow-up period 3 mths (15 days-15 mths). Based on the history and ECG flecainide had been effective in 51 pts. The improvement was most pronounced in pts suffering from supraventricular tachycardia involving an accessory bypass tract (84-92{\%}). Flecainide had been discontinued in 50 pts due to: insufficient effect in 28, side effects in 17 and for other reasons in 5. The side effects indicating flecainide withdrawal (pts) were: cerebral symptoms (4), gastrointestinal complaints (2), bradyarrhythmias (2), heart failure (3) and suspected pro-arrhythmia (4). (Ventricular tachycardia in 3, 1:1 AV-conducting during atrial flutter in 1).",
keywords = "Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Atrial Fibrillation, Atrial Flutter, Cardiac Complexes, Premature, Child, Dose-Response Relationship, Drug, Electrocardiography, Female, Flecainide, Heart Ventricles, Humans, Male, Middle Aged, Prospective Studies, Tachycardia, Tachycardia, Supraventricular",
author = "F Frandsen and P Pless and H Mickley and M M{\o}ller",
year = "1990",
language = "English",
volume = "45",
pages = "351--7",
journal = "Acta Cardiologica",
issn = "0001-5385",
publisher = "La/Societe Belge de Cardiologie",
number = "5",

}

Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients. / Frandsen, F; Pless, P; Mickley, H; Møller, M.

I: Acta Cardiologica, Bind 45, Nr. 5, 1990, s. 351-7.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients

AU - Frandsen, F

AU - Pless, P

AU - Mickley, H

AU - Møller, M

PY - 1990

Y1 - 1990

N2 - The long-term clinical effect of oral flecainide treatment was evaluated in 107 pts (10-82 yrs). Indications for treatment were: atrial fibrillation 38%, atrial flutter 16%, ventricular tachycardia 24%, ventricular ectopic beats 10% and supraventricular tachycardia 12%. Daily flecainide dosage was 200 (100-400) mg. Follow-up period 3 mths (15 days-15 mths). Based on the history and ECG flecainide had been effective in 51 pts. The improvement was most pronounced in pts suffering from supraventricular tachycardia involving an accessory bypass tract (84-92%). Flecainide had been discontinued in 50 pts due to: insufficient effect in 28, side effects in 17 and for other reasons in 5. The side effects indicating flecainide withdrawal (pts) were: cerebral symptoms (4), gastrointestinal complaints (2), bradyarrhythmias (2), heart failure (3) and suspected pro-arrhythmia (4). (Ventricular tachycardia in 3, 1:1 AV-conducting during atrial flutter in 1).

AB - The long-term clinical effect of oral flecainide treatment was evaluated in 107 pts (10-82 yrs). Indications for treatment were: atrial fibrillation 38%, atrial flutter 16%, ventricular tachycardia 24%, ventricular ectopic beats 10% and supraventricular tachycardia 12%. Daily flecainide dosage was 200 (100-400) mg. Follow-up period 3 mths (15 days-15 mths). Based on the history and ECG flecainide had been effective in 51 pts. The improvement was most pronounced in pts suffering from supraventricular tachycardia involving an accessory bypass tract (84-92%). Flecainide had been discontinued in 50 pts due to: insufficient effect in 28, side effects in 17 and for other reasons in 5. The side effects indicating flecainide withdrawal (pts) were: cerebral symptoms (4), gastrointestinal complaints (2), bradyarrhythmias (2), heart failure (3) and suspected pro-arrhythmia (4). (Ventricular tachycardia in 3, 1:1 AV-conducting during atrial flutter in 1).

KW - Administration, Oral

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Atrial Fibrillation

KW - Atrial Flutter

KW - Cardiac Complexes, Premature

KW - Child

KW - Dose-Response Relationship, Drug

KW - Electrocardiography

KW - Female

KW - Flecainide

KW - Heart Ventricles

KW - Humans

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Tachycardia

KW - Tachycardia, Supraventricular

M3 - Journal article

VL - 45

SP - 351

EP - 357

JO - Acta Cardiologica

JF - Acta Cardiologica

SN - 0001-5385

IS - 5

ER -